Comparison of patient characteristics at diagnosis
| Characteristics . | Patients with variant translocations (n = 30) . | Patients without variant translocations (n = 529) . | P . |
|---|---|---|---|
| Median age, y (range) | 52 (33-84) | 52 (18-80) | .49 |
| Sex, male/female; n (%) | 19/11 (63/37) | 317/212 (60/40) | .85 |
| Spleen, cm; median (range) | 1.5 (0-18) | 1 (0-24) | .76 |
| Median hemoglobin level, g/L (range) | 11.8 (7.9-16.1) | 12.2 (6.4-17.5) | .41 |
| Median platelet count, 109/L (range) | 317 (124-1364) | 353 (100-4920) | .36 |
| Peripheral blasts, %; median (range) | 2 (0-5) | 1 (0-10) | .55 |
| Eosinophils, %; median (range) | 2 (0-6) | 2 (0-15) | .89 |
| Basophils, %; median (range) | 2 (0-5) | 2 (0-19) | .08 |
| Sokal risk score | |||
| low | 13 (43) | 206 (39) | .81 |
| intermediate | 7 (23) | 209 (40) | |
| high | 10 (33) | 114 (22) | |
| Hasford risk score | |||
| low | 10 (33) | 229 (43) | .69 |
| intermediate | 15 (50) | 266 (50) | |
| high | 5 (17) | 34 (6) | |
| Additional cytogenetic abnormalities | 1 (3) | 20 (4) | 1.00 |
| Deletion der(9) | 6 (20) | 54 (10) | .12 |
| Imatinib dose | |||
| 400 mg | 20 (67) | 403 (76) | .27 |
| 800 mg | 10 (33) | 126 (24) |
| Characteristics . | Patients with variant translocations (n = 30) . | Patients without variant translocations (n = 529) . | P . |
|---|---|---|---|
| Median age, y (range) | 52 (33-84) | 52 (18-80) | .49 |
| Sex, male/female; n (%) | 19/11 (63/37) | 317/212 (60/40) | .85 |
| Spleen, cm; median (range) | 1.5 (0-18) | 1 (0-24) | .76 |
| Median hemoglobin level, g/L (range) | 11.8 (7.9-16.1) | 12.2 (6.4-17.5) | .41 |
| Median platelet count, 109/L (range) | 317 (124-1364) | 353 (100-4920) | .36 |
| Peripheral blasts, %; median (range) | 2 (0-5) | 1 (0-10) | .55 |
| Eosinophils, %; median (range) | 2 (0-6) | 2 (0-15) | .89 |
| Basophils, %; median (range) | 2 (0-5) | 2 (0-19) | .08 |
| Sokal risk score | |||
| low | 13 (43) | 206 (39) | .81 |
| intermediate | 7 (23) | 209 (40) | |
| high | 10 (33) | 114 (22) | |
| Hasford risk score | |||
| low | 10 (33) | 229 (43) | .69 |
| intermediate | 15 (50) | 266 (50) | |
| high | 5 (17) | 34 (6) | |
| Additional cytogenetic abnormalities | 1 (3) | 20 (4) | 1.00 |
| Deletion der(9) | 6 (20) | 54 (10) | .12 |
| Imatinib dose | |||
| 400 mg | 20 (67) | 403 (76) | .27 |
| 800 mg | 10 (33) | 126 (24) |